Allogeneic Marrow Transplantation

References

• Jacobson L O, Simmons E L, Marks E K, et al. The role of the spleen in radiation injury and recovery. J Lab Clin Med 1950; 35: 746–770
   PubMed Web of Science ®Google Scholar
• Lorenz E, Uphoff D, Reid T R, et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951; 12: 197–201
   PubMed Web of Science ®Google Scholar
• Gatti R A, Meuwissen H J, Allen H D, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968; 2: 1366–1369
   PubMed Web of Science ®Google Scholar
• Thomas E D, Storb R, Clift R A, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843, 292: 895–902
   PubMed Web of Science ®Google Scholar
• Pahwa R, Pahwa S, O'Reilly R, Good R A. Treatment of the immunodeficiency diseases—Progress toward replacement therapy emphasizing cellular and macromolecular engineering. Springer Semin Immunopathol 1978; 1: 355–404
   Web of Science ®Google Scholar
• Storb R, Thomas E D, Weiden P L, et al. Aplastic anemia treated by allogeneic bone marrow transplantation: A report on 49 new cases from Seattle. Blood 1976; 48: 817–841
   PubMed Web of Science ®Google Scholar
• Hobbs J R. Bone marrow transplantation for inborn errors. Lancet 1981; 2: 735–739
   PubMed Web of Science ®Google Scholar
• Bodmer W F. The HLA system. Br Med Bull 1978; 34: 213–316
   PubMedGoogle Scholar
• Clift R A, Hansen J A, Thomas E D, et al. Marrow transplantation from donors other than HLA-identical siblings. Transplantation 1979; 28: 235–242
   PubMed Web of Science ®Google Scholar
• Santos G W, Sensenbrenner L L, Burke P J, et al. The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc 1972; 4: 559–604
   PubMed Web of Science ®Google Scholar
• Thomas E D, Buckner C D, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511–533
   PubMed Web of Science ®Google Scholar
• Thomas E D, Clift R A, Hersman J, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation. Int J Rad Oncol Biol Phys 1982; 8: 817–821
   PubMed Web of Science ®Google Scholar
• The UCLA Bone Marrow Transplantation Group. Bone marrow transplantation with intensive combination chemotherapy/radiation therapy (SCARI) in acute leukemia. Ann Intern Med 1977; 86: 155–161
   PubMed Web of Science ®Google Scholar
• Badger C, Buckner C D, Thomas E D, et al. Allogeneic marrow transplantation for acute leukemia in relapse. Leuk Res 1982; 6: 383–387
   PubMed Web of Science ®Google Scholar
• Ramsay N KC, Kim T, Nesbit M E, et al. Total lymphoid irradiation and cyclophosphamide as preparation for bone marrow transplantation in severe aplastic anemia. Blood 1980; 55: 344–346
   PubMed Web of Science ®Google Scholar
• Gale R P, Ho W, Feig S, et al. Prevention of graft rejection following bone marrow transplantation. Blood 1981; 57: 9–12
   PubMed Web of Science ®Google Scholar
• Gluckman E, Barrett A J, Arcese W, et al. Bone marrow transplantation in severe aplastic anemia—A survey of the European Group for Bone Marrow Transplantation. Br J Haematol 1981; 49: 165–173
   PubMed Web of Science ®Google Scholar
• Parkman R, Rappeport J, Geha R, et al. Complete correction of the Wiskott-Aldrich Syndrome by allogeneic bone-marrow transplantation. N Engl J Med 1978; 298: 921–927
   PubMedGoogle Scholar
• Kapoor N, Kirkpatrick D, Blaese R M, et al. Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. Blood 1981; 57: 692–696
   PubMed Web of Science ®Google Scholar
• Ochs H D, Lum L G, Johnson F L, et al. Bone marrow transplantation in the Wiskott-Aldrich syndrome: Complete hematologic and immunologic reconstitution. Transplantation 1982; 34: 284–288
   PubMed Web of Science ®Google Scholar
• Thomas E D, Buckner C D, Sanders J, et al. Marrow transplantation for thalassemia. Lancet 1982; 2: 227–228
   PubMed Web of Science ®Google Scholar
• Thomas E D, Storb R. Technique for human marrow grafting. Blood 1970; 36: 507–515
   PubMed Web of Science ®Google Scholar
• Witherspoon R P, Schanfield M S, Storb R, Thomas E D, Giblett E R. Immunoglobulin production of donor origin after marrow transplantation for acute leukemia or aplastic anemia. Transplantation 1978; 26: 407–408
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Parkman R. The pathophysiology and treatment of graft-versus-host disease. Clinics in Haematology, D Nathan. Number 3, Saunders, Ltd, London 1983; Vol 12: 775–789
   Google Scholar
• Storb R, Epstein R B, Graham T C, Thomas E D. Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240–246
   PubMed Web of Science ®Google Scholar
• Powles R L, Clink H M, Spence D, et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bonemarrow transplantation. Lancet 1980; 1: 327–329
   PubMed Web of Science ®Google Scholar
• Shulman H, Striker G, Deeg H J, et al. Nephrotoxicity of Cyclosporin A after allogeneic marrow transplantation: Glomerular thromboses and tubular injury. N Engl J Med 1981; 305: 1392–1395
   PubMed Web of Science ®Google Scholar
• Tutschka P J, Beschorner W E, Hess A D, et al. Cyclosporine A to prevent graft-versus-host disease: A pilot study in 22 patients receiving allogeneic marrow transplants. Blood 1983; 61: 318–325
   PubMed Web of Science ®Google Scholar
• Deeg H J, Storb R, Thomas E D, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: Preliminary results of a randomized trial comparing cyclosporine and methotrexate for the prophylaxis of graft-versus-host disease. Transplant Proc, in press
   Google Scholar
• Storb R, Doney K C, Thomas E D, et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982; 59: 236–246
   PubMed Web of Science ®Google Scholar
• Bortin M M, Gale R P, Rimm A A. for the Advisory Committee of the International Bone Marrow Transplant Registry: Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. J Am Med Assoc 1981; 245: 1132–1139
   PubMedGoogle Scholar
• Camitta B M, Thomas E D, Nathan D G, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979; 53: 504–514
   PubMed Web of Science ®Google Scholar
• Storb R, Thomas E D, Buckner C D, et al. Marrow transplantation in thirty “untransfused” patients with severe aplastic anemia. Ann Intern Med 1980; 92: 30–36
   PubMed Web of Science ®Google Scholar
• Speck B, Gratwohl A, Nissen C, et al. Treatment of severe aplastic anemia with antilymphocyte globulin or bone marrow transplantation. Br Med J 1981; 282: 860–863
   PubMed Web of Science ®Google Scholar
• Camitta B, O'Reilly R J, Sensenbrenner L, et al. Severe aplastic anemia: A controlled trial of antilymphocyte globulin therapy. Blood 1982; 60: 165a, abstract
   Google Scholar
• Santos G W, Kaizer H. Bone marrow transplantation in acute leukemia. Sem Hematol 1982; 19: 227–240
   PubMed Web of Science ®Google Scholar
• Thomas E D, Buckner C D, Clift R A, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597–599
   PubMed Web of Science ®Google Scholar
• Powles R L, Morgenstern G, Clink H M, et al. The place of bone-marrow transplantation in acute myelogenous leukemia. Lancet 1980; 1: 1047–1050
   PubMed Web of Science ®Google Scholar
• Blume K G, Beutler E, Bross K J, et al. Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 1980; 302: 1041–1046
   PubMed Web of Science ®Google Scholar
• Kersey J H, Ramsay N KC, Kim T, et al. Allogeneic bone marrow transplantation in acute nonlymphocytic leukemia: A pilot study. Blood 1982; 60: 400–403
   PubMed Web of Science ®Google Scholar
• Buckner C D, Clift R A, Thomas E D, et al. Allogeneic marrow transplantation for patients with acute non-lymphoblastic leukemia in second remission. Leuk Res 1982; 6: 395–399
   PubMed Web of Science ®Google Scholar
• Appelbaum F R, Clift R A, Buckner C D, et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood 1983; 61: 949–953
   PubMed Web of Science ®Google Scholar
• Thomas E D, Sanders J E, Flournoy N, et al. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood 1979; 54: 468–476
   PubMed Web of Science ®Google Scholar
• Johnson F L, Thomas E D, Clark B S, et al. A comparison of marrow transplantation to chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission. N Engl J Med 1981; 305: 846–851
   PubMed Web of Science ®Google Scholar
• Fefer A, Cheever M A, Greenberg P D, et al. Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med 1982; 306: 63–68
   PubMed Web of Science ®Google Scholar
• Doney K C, Buckner C D, Thomas E D, et al. Allogeneic bone marrow transplantation for chronic granulocytic leukemia. Exp Hematol 1981; 9: 966–971
   PubMed Web of Science ®Google Scholar
• Clift R A, Buckner C D, Thomas E D, et al. The treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 1982; 2: 621–624
   PubMed Web of Science ®Google Scholar
• Champlin R, Ho W, Arenson E, Gale R P. Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Blood 1982; 30: 1038–1041
   Google Scholar
• Goldman J M, Baughan A SJ, McCarthy D M, et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet 1982; 2: 623–625
   PubMed Web of Science ®Google Scholar
• Smith J W, Shulman H M, Thomas E D, et al. Bone marrow transplantation for acute myelosclerosis. Cancer 1981; 48: 2198–2203
   PubMed Web of Science ®Google Scholar
• Wolf J L, Spruce W E, Bearman R M, et al. Reversal of acute (“malignant”) myelosclerosis by allogeneic bone marrow transplantation. Blood 1982; 59: 191–193
   PubMed Web of Science ®Google Scholar
• Cheever M A, Fefer A, Greenberg P D, et al. Treatment of hairy cell leukemia with chemoradiotherapy and identical twin bone marrow transplantation. N Engl J Med 1982; 307: 479–481
   PubMed Web of Science ®Google Scholar
• Appelbaum F R, Fefer A, Cheever M A, et al. Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. Blood 1981; 58: 509–513
   PubMed Web of Science ®Google Scholar
• Osserman E F, DiRe L B, DiRe J, et al. Identical twin transplantation in multiple myeloma. Acta Haematol 1982; 68: 215–223
   PubMed Web of Science ®Google Scholar
• Coccia P F, Krivit W, Cervenka J, et al. Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med 1980; 302: 701–708
   PubMed Web of Science ®Google Scholar
• Rappeport J M, Parkman R, Newburger P, et al. Correction of infantile agranulocytosis (Kostmann's syndrome) by allogeneic bone marrow transplantation. Am J Med 1980; 68: 605–609
   PubMed Web of Science ®Google Scholar
• O'Reilly R J, Pahwa R, Dupont B, et al. Severe combined immunodeficiency: Transplantation approaches for patients lacking an HLA genotypically identical sibling. Transplant Proc 1978; 10: 187–198
   PubMed Web of Science ®Google Scholar
• Fass L, Ochs H D, Thomas E D, et al. Studies of immunological reactivity following syngeneic or allogeneic marrow grafts in man. Transplantation 1973; 16: 630–640
   PubMed Web of Science ®Google Scholar
• Elfenbein G J, Anderson P N, Humphrey R L, et al. Immune system reconstitution following allogeneic bone marrow transplantation in man: A multiparameter analysis. Transplant Proc 1976; 8: 641–646
   PubMed Web of Science ®Google Scholar
• Noel, Dr, Witherspoon R P, Storb R, et al. Does graft-versus-host disease influence the tempo of immunologic recover after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood 1978; 51: 1087–1105
   PubMed Web of Science ®Google Scholar
• Witherspoon R P, Kopecky K, Storb R F, et al. Immunological recovery in 48 patients following syngeneic marrow transplantation for hematological malignancy. Transplantation 1982; 33: 143–149
   PubMed Web of Science ®Google Scholar
• Witherspoon R P, Storb R, Ochs H D, et al. Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981; 58: 360–368
   PubMed Web of Science ®Google Scholar
• Sosa R, Weiden P L, Storb R, et al. Granulocyte function in human allogeneic marrow graft recipients. Exp Hematol 1980; 8: 1183–1189
   PubMed Web of Science ®Google Scholar
• Friedrich W, O'Reilly R J, Koziner B, et al. T-Lymphocyte reconstitution in recipients of bone marrow transplants with and without GVHD: Imbalances of T-cell subpopulations having unique regulatory and cognitive function. Blood 1982; 59: 696–701
   PubMed Web of Science ®Google Scholar
• Atkinson K, Hansen J A, Storb R, et al. T-Cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets. Blood 1982; 59: 1292–1298
   PubMed Web of Science ®Google Scholar
• Livnat S, Seigneuret M, Storb R, et al. Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation. J Immunol 1980; 124: 481–490
   PubMed Web of Science ®Google Scholar
• Ringden O, Witherspoon R, Storb R, et al. B cell function in human marrow transplant recipients assessed by direct and indirect hemolysis-in-gel assays. J Immunol 1979; 123: 2729–2734
   PubMed Web of Science ®Google Scholar
• Lum L G, Seigneuret M C, Storb R F, et al. In vitro regulation of immunoglobulin synthesis after marrow transplantation. I. T-Cell and B-Cell deficiencies in patients with and without chronic graft-versus-host disease. Blood 1981; 58: 431–439
   PubMed Web of Science ®Google Scholar
• Witherspoon R P, Lum L G, Storb R, et al. In vitro regulation of immunoglobulin synthesis after human marrow transplantation. II. Deficient T and non-T lymphocyte function within 34-months of allogeneic, syngeneic, or autologous marrow grafting for hematologic malignancy. Blood 1982; 59: 844–850
   PubMed Web of Science ®Google Scholar
• Winston D J, Gale R P, Meyer D V, et al. Infectious complications of human bone marrow transplantation. Medicine 1979; 58: 1–31
   PubMed Web of Science ®Google Scholar
• Meyers J D, Thomas E D. Infection complicating bone marrow transplantation. Clinical Approach to Infection in the Immunocompromised Host, R H Rubin, L S Young. Plenum Press, New York 1982; 507–551, Chap 15
   Google Scholar
• Neiman P E, Reeves W, Ray G, et al. A prospective analysis of interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J Infect Dis 1977; 136: 754–767
   PubMed Web of Science ®Google Scholar
• O'Reilly R J, Riech L, Gold J, et al. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: Preliminary results. Transplant Proc 1983; 15: 1405–1411
   Web of Science ®Google Scholar
• Meyers J D, Leszczynski J, Zaia J A, et al. Successful prevention of cytomegalovirus infection after marrow transplant with cytomegalovirus immune globulin. Ann Intern Med 1983; 98: 442–446
   PubMed Web of Science ®Google Scholar
• Atkinson K, Meyers J D, Storb R, et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29: 47–50
   PubMed Web of Science ®Google Scholar
• Atkinson Farewell K. V, Storb R, et al. Analysis of late infections after human bone marrow transplantation: Role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982; 60: 714–720
   PubMed Web of Science ®Google Scholar
• Atkinson K, Storb R, Prentice R L, et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979; 53: 720–731
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304
   PubMed Web of Science ®Google Scholar
• Sale G E, Lerner K G, Barker E A, et al. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 1977; 89: 621–635
   PubMed Web of Science ®Google Scholar
• Epstein R J, McDonald G B, Sale G E, et al. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: A prospective study of thirteen patients. Gastroenterology 1980; 78: 764–771
   PubMed Web of Science ®Google Scholar
• Shulman H M, McDonald G B, Matthews D, et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79: 1178–1191
   PubMed Web of Science ®Google Scholar
• Weiden P L, and the Seattle. Marrow Transplant Team: Graft-vs-host disease in allogeneic marrow transplantation. Biology of Bone Marrow Transplantation, R P Gale, C F Fox. Academic Press, New York 1980; 37–48
   Google Scholar
• Storb R, Prentice R L, Buckner C D, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302–307
   PubMed Web of Science ®Google Scholar
• Doney K C, Weiden P I, Storb R, et al. Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 1981; 31: 141–143
   PubMed Web of Science ®Google Scholar
• Weiden P L, Doney Storb K. R, et al. Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts. Transplantation 1979; 27: 227–230
   PubMed Web of Science ®Google Scholar
• Ramsay N KC, Kersey J H, Robison L L, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306: 392–397
   PubMed Web of Science ®Google Scholar
• Zwaan F E, Hermans J. for the EBMT—Leukaemia Working Party: Bone-marrow transplantation for leukaemia—European results in 264 cases. Exp Hematol 1982; 10(suppl 11)47, abstract
   Google Scholar
• Van Bekkum D W, Roodenburg J, Heidt P J, van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401–404
   PubMed Web of Science ®Google Scholar
• Rodt H V, Thierfelder S, Eulitz M. Suppression of acute secondary disease by heterologous anti-brain serum. Blut 1972; 25: 385–389
   PubMedGoogle Scholar
• Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978; 148: 1687–1698
   PubMed Web of Science ®Google Scholar
• Rodt H, Kolb H J, Netzel B, et al. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant Proc 1981; 13: 257–261
   PubMed Web of Science ®Google Scholar
• Prentice H G, Janossy G, Skeggs D, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet 1982; 1: 700–703
   PubMed Web of Science ®Google Scholar
• Filipovich A H, Ramsay N KC, Warkentin P I, et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet 1982; 1: 1266–1269
   PubMed Web of Science ®Google Scholar
• O'Reilly R J, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency (SCID) with histoin-compatible parental marrow fractionated by soybean agglutinin and sheep red blood cells. Transplant Proc 1983; 15: 1431–1435
   Web of Science ®Google Scholar
• Doney K C, Weiden P L, Storb R, et al. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11: 1–18
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Shulman H M, Weiden P L, . The spectrum of chronic graft-vs-host disease in man. Biology of Bone Marrow Transplantation, R P Gale, C F Fox, et al. Academic Press, New York 1980; 69–73
   Google Scholar
• Shulman H M, Sale G E, Lerner K G, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545–570
   PubMed Web of Science ®Google Scholar
• Shulman H M, Sullivan K M, Weiden P L, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathological study of 20 Seattle patients. Am J Med 1980; 69: 204–217
   PubMed Web of Science ®Google Scholar
• Gratwohl A A, Moutsopoulos H M, Chused T M, et al. Sjogren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med 1977; 87: 703–706
   PubMed Web of Science ®Google Scholar
• Sale G E, Shulman H M, Schubert M M, et al. Oral and ophthalmic pathology of graft versus host disease in man: Predictive value of the lip biopsy. Hum Pathol 1981; 12: 1022–1030
   PubMed Web of Science ®Google Scholar
• McDonald G B, Sullivan K M, Schuffler M D, et al. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology 1981; 80: 914–921
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Shulman H M, Storb R, et al. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267–276
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Dahlberg S, Storb R, et al. Chronic graft-versus-host disease (GVHD): Risk factor analysis in patients surviving > 70 days after marrow transplantation. Exp Hematol 1982; 10: 7, abstract
   Web of Science ®Google Scholar
• Storb R, Prentice R L, Sullivan K M, et al. Pediatric factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461–466
   PubMed Web of Science ®Google Scholar
• Sullivan K M, Storb R, Flournoy N, et al. Day 100 screening studies predict development of chronic graft-vs-host disease. Blood 1981; 58: 176a, abstract
   Google Scholar
• Sullivan K M, Storb R, Flournoy N, et al. Preliminary analysis of a randomized trial of immunosuppressive therapy of chronic graft-vs-host disease. Blood 1982; 60: 173a, abstract
   Google Scholar
• Forman S J, Farbstein M J, Scott E P, et al. Prevention and therapy of graft-versus-host disease. N Engl J Med 1982; 307: 376, letter
   PubMedGoogle Scholar
• Atkinson K, Incefy G S, Storb R, et al. Low serum thymic hormone levels in patients with chronic graft-versus-host disease. Blood 1982; 59: 1073–1077
   PubMed Web of Science ®Google Scholar
• Atkinson K, Storb R, Ochs H D, et al. Thymus transplantation after allogeneic bone marrow graft to prevent chronic graft-versus-host disease in humans. Transplantation 1982; 33: 168–173
   PubMed Web of Science ®Google Scholar
• Tsoi M S, Storb R, Dobbs S, et al. Cell-mediated immunity to non-HLA antigens of the host by donor lymphocytes in patients with chronic graft-vs-host disease. I Immunol 1980; 125: 2258–2262
   PubMed Web of Science ®Google Scholar
• Tsoi M S, Storb R, Dobbs S, et al. Specific suppressor cells in graft-host tolerance of HLA-identical marrow transplantation. Nature (London) 1981; 292: 355–357
   PubMed Web of Science ®Google Scholar
• Tsoi M S, Storb R, Dobbs S, et al. Nonspecific suppressor cells in patients with chronic graft-vs-host disease after marrow grafting. J Immunol 1979; 123: 1970–1976
   PubMed Web of Science ®Google Scholar
• Hansen J A, Clift R A, Thomas E D, et al. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980; 303: 565–567
   PubMed Web of Science ®Google Scholar
• Newburger P E, Latt S A, Pesando J M, et al. Leukemia relapse in donor cells after allogeneic bone-marrow transplantation. N Engl J Med 1981; 304: 712–714
   PubMed Web of Science ®Google Scholar
• Schubach W H, Hackman R, Neiman P E, et al. A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. Blood 1982; 60: 180–187
   PubMed Web of Science ®Google Scholar
• Clift R A, Buckner C D, Thomas E D, et al. Allogeneic marrow transplantation using fractionated total body irradiation in patients with acute lymphoblastic leukemia in relapse. Leuk Res 1982; 6: 401–407
   PubMed Web of Science ®Google Scholar
• Buckner C D, Clift R A, Thomas E D, et al. Allogeneic marrow transplantation for acute non-lymphoblastic leukemia in relapse using fractionated total body irradiation. Leuk Res 1982; 6: 389–394
   PubMed Web of Science ®Google Scholar
• Barnes D WH, Corp M J, Loutit J F, et al. Treatment of murine leukaemia with x rays and homologous bone marrow. Primary communication. Br Med J 1956; 2: 626–627
   PubMed Web of Science ®Google Scholar
• Mathe G, Amiel J L, Schwarzenberg L, et al. Adoptive immunotherapy of acute leukemia: Experimental and clinical results. Cancer Res 1965; 25: 1525–1531
   PubMed Web of Science ®Google Scholar
• Fefer A, Einstein A B, Cheever A B. Adoptive chemoimmunotherapy of cancer in animals: A review of results, principles and problems. Ann NY Acad Sci 1976; 277: 492–504
   PubMed Web of Science ®Google Scholar
• Odom L F, August C S, Githens J H, et al. Remission of relapsed leukaemia during a graft-versus-host reaction. A “graft-versus-leukaemia reaction” in man? Lancet 1978; 2: 537–540
   Google Scholar
• Weiden P L, Flournoy N, Thomas E D, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073
   PubMed Web of Science ®Google Scholar
• Weiden P L, Sullivan K M, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529–1533
   PubMed Web of Science ®Google Scholar